IGFBP-1 in Cardiometabolic Pathophysiology—Insights From Loss-of-Function and Gain-of-Function Studies in Male Mice
Open Access
- 4 November 2019
- journal article
- research article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 4 (1) , bvz006
Abstract
We have previously reported that overexpression of human insulin-like growth factor binding protein (IGFBP)-1 in mice leads to vascular insulin sensitization, increased nitric oxide bioavailability, reduced atherosclerosis, and enhanced vascular repair, and in the setting of obesity improves glucose tolerance. Human studies suggest that low levels of IGFBP-1 are permissive for the development of diabetes and cardiovascular disease. Here we seek to determine whether loss of IGFBP-1 plays a causal role in the predisposition to cardiometabolic disease. Metabolic phenotyping was performed in transgenic mice with homozygous knockout of IGFBP-1. This included glucose, insulin, and insulin-like growth factor I tolerance testing under normal diet and high-fat feeding conditions. Vascular phenotyping was then performed in the same mice using vasomotor aortic ring studies, flow cytometry, vascular wire injury, and angiogenesis assays. These were complemented with vascular phenotyping of IGFBP-1 overexpressing mice. Metabolic phenotype was similar in IGFBP-1 knockout and wild-type mice subjected to obesity. Deletion of IGFBP-1 inhibited endothelial regeneration following injury, suggesting that IGFBP-1 is required for effective vascular repair. Developmental angiogenesis was unaltered by deletion or overexpression of IGFBP-1. Recovery of perfusion following hind limb ischemia was unchanged in mice lacking or overexpressing IGFBP-1; however, overexpression of IGFBP-1 stimulated hindlimb perfusion and angiogenesis in insulin-resistant mice. These findings provide new insights into the role of IGFBP-1 in metabolic and vascular pathophysiology. Irrespective of whether loss of IGFBP-1 plays a causal role in the development of cardiometabolic disorders, increasing IGFBP-1 levels appears effective in promoting neovascularization in response to ischemia.Keywords
Funding Information
- British Heart Foundation
- British Heart Foundation Clinical Research
- British Heart Foundation clinical
- British Heart Foundation Chair in Cardiology
- European Research Council Starting
This publication has 46 references indexed in Scilit:
- Increasing Circulating IGFBP1 Levels Improves Insulin Sensitivity, Promotes Nitric Oxide Production, Lowers Blood Pressure, and Protects Against AtherosclerosisDiabetes, 2012
- Insulin Resistance Impairs Circulating Angiogenic Progenitor Cell Function and Delays Endothelial RegenerationDiabetes, 2011
- Regeneration of the Endothelium in Vascular InjuryCardiovascular Drugs and Therapy, 2010
- Intraperitoneal Fat and Insulin Resistance in Obese AdolescentsObesity, 2010
- Antidiabetic Effects of IGFBP2, a Leptin-Regulated GeneCell Metabolism, 2010
- Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): The Söderåkra Cardiovascular Risk Factor StudyDiabetes & Metabolism, 2009
- Regulation of Insulin-Response Element Binding Protein-1 in Obesity and Diabetes: Potential Role in Impaired Insulin-Induced Gene TranscriptionEndocrinology, 2008
- Hepatic IGFBP1 is a prosurvival factor that binds to BAK, protects the liver from apoptosis, and antagonizes the proapoptotic actions of p53 at mitochondriaGenes & Development, 2007
- Optimized Fibrin Gel Bead Assay for the Study of AngiogenesisJournal of Visualized Experiments, 2007
- Site‐directed mutagenesis of the N‐terminal region of IGF binding protein 1; analysis of IGF binding capabilityFEBS Letters, 1991